Find A Physician
More on For High Blood Pressure Patients, Preventing or Reducing Enlarged Heart May Decrease Risk for Diabetes
Hospital News
More on For High Blood Pressure Patients, Preventing or Reducing Enlarged Heart May Decrease Risk for Diabetes
- Americans Encouraged to Make Many Lifestyle Changes, Not Just One, to Reduce Cardiovascular Risk
- Columbia Research Suggests Need to Rethink Causes of Heart Failure
- Columbia Scientists Study Advantages of Using Web to Tailor Medical Information to Patients
- Comprehensive Review Finds Job Stress Does Not Contribute to Chronic High Blood Pressure
- Diabetics Benefit Less from Anti-Hypertensive Treatment to Reduce Enlarged Heart
- Electrocardiogram Helps Predict Risk for Congestive Heart Failure in Hypertensive Patients
- For High-Blood-Pressure Patients, Preventing or Reducing Enlarged Heart Decreases Risk of Heart Failure
- Genetic Medicine Program at Weill Cornell Receives Major Boost from The Starr Foundation
- Health Effects of Secondhand Smoke Studied in First-of-Its-Kind Series of Clinical Studies
- Hot Flashes in Women Linked to High Blood Pressure, According to New Weill Cornell Study
- Job Strain Linked to High Blood Pressure, Heart Disease Risk
- Larger Waistline Is Linked to Increased Risk for Heart Disease in Women
- Lovastatin Treatment Reduces Events in Patients at Varying Degrees of Coronary Risk and Reduces Need for Invasive Procedures
- Message to the Elderly: It's Never Too Late to Prevent Illness!
- New Laser Technology Offers Promise for Heart Disease Patients
- New Treatment for Enlarged Heart Effective, NewYork Weill Cornell Study Shows
- NewYork-Presbyterian/Columbia Announces State-of-the-Art, Vivian and Seymour Milstein Family Heart Center in Washington Heights
- NewYork Weill Cornell Research Highlights Need To Focus on Frequently Neglected Neurogenic Hypertension
- Reducing Enlarged Heart Muscle Cuts Patients' Cardiac Risk, Independent of Lowered Blood Pressure, NewYork-Presbyterian/Weill Cornell Researchers Report
- Researcher Predicts Paradigm Shift in Heart Disease Treatment
- Research Shows Cholesterol-Lowering Drug Lovastatin Reduces Risk of Heart Attack in Healthy Adults
- Scientific Evidence Points to Male Biological Clock
- The Mind/Body Link in Essential Hypertension: Time for a New Paradigm
- Weill Cornell Physician-Scientists Win 2 Top Awards at American Heart Association Meeting
- Weill Cornell Receives $7.6 Million Federal Grant for Clinical Trials on New Ways To Change Behavior in Patients With Cardiopulmonary Disease
- Weill Cornell Researcher Shows How Progesterone Is Not Just Sex Hormone but Blood Pressure Hormone
- Weill Cornell Researchers Identify a Likely Genetic Cause of Atherosclerosis
Research and Clinical Trials
More on For High Blood Pressure Patients, Preventing or Reducing Enlarged Heart May Decrease Risk for Diabetes
Health Library
More on For High Blood Pressure Patients, Preventing or Reducing Enlarged Heart May Decrease Risk for Diabetes
Clinical Services
More on For High Blood Pressure Patients, Preventing or Reducing Enlarged Heart May Decrease Risk for Diabetes
- Advanced Diagnostics
- Alcohol Septal Ablation
- Angiograms
- Cardiac Magnetic Resonance Imaging (MRI)
- Cardiac Rehabilitation
- Cardiology
- Diabetes and Endocrinology
- Echocardiograms
- Electrocardiograms (ECGs), Stress Tests, Holter Monitor and Event/Loop Recorders
- Intravascular / Intracoronary and Intracardiac Ultrasound
- Nuclear Imaging For Heart Disease (PET scans, MUGA scans)
- Transmyocardial Revascularization
For High Blood Pressure Patients, Preventing or Reducing Enlarged Heart May Decrease Risk for Diabetes
NewYork-Presbyterian/Weill Cornell Findings, Published in November Journal Hypertension
NEW YORK (Oct 31, 2007)
High-blood-pressure patients treated for enlarged heart (left ventricular hypertrophy, LVH) who have regression or prevention of LVH may also have a better chance of preventing diabetes. Led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, the research is published in the November Hypertension, a journal of the American Heart Association (AHA).
An estimated 20 percent of all high–blood–pressure patients, or 12 million Americans, have LVH and are at increased risk of developing diabetes.
The study reports a 38–percent reduced risk of developing diabetes for high–blood–pressure patients who demonstrated regression of LVH during treatment for high blood pressure, with a 26–percent reduced risk after adjusting for other risk factors for diabetes. The reduction in risk of diabetes was independent of treatment type and of the degree of blood pressure change in this population.
"A healthy heart is a prerequisite for the health of the body as a whole. Our previous research has shown that treating enlarged heart in high-blood-pressure patients reduces the risk for a variety of cardiovascular conditions. This new study finds an important new benefit—namely a better chance of avoiding diabetes among patients who exhibit a reduction of their hypertrophy during treatment," says the study's principal investigator, Dr. Peter Okin, director of clinical affairs and professor of medicine in the Greenberg Division of Cardiology at Weill Cornell Medical College and attending physician at NewYork-Presbyterian/Weill Cornell.
An editorial about the study in the journal notes that "the study by Okin et al extends our knowledge and understanding of the importance of LVH reversal by showing the beneficial metabolic effects of treatment–induced regression of LVH in a large series of patients with hypertensive heart disease."
Unfortunately, for high–blood–pressure patients who already have diabetes, high blood pressure treatment is less effective at reducing their LVH compared to patients without diabetes. In addition, regression of LVH in hypertensive patients with diabetes does not appear to be associated with a reduction in cardiovascular events, according to a 2006 study by Dr. Okin and colleagues, making prevention of diabetes in patients with hypertension an important goal.
The study used data from the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study conducted between 1995 and 2001. In the blinded study, patients received daily 50 mg doses of either losartan or atenolol.
Co-authors of the current study included Drs. Richard B. Devereux of NewYork-Presbyterian/Weill Cornell and Weill Cornell Medical College, and physician-scientists from Merck Research Laboratories (Upper Gwynedd, Pa.), Sahlgrenska University Hospital/Östra (Sweden), Ullevål University Hospital (Norway) and Umeå University (Sweden).
The study was supported in part by a grant from Merck & Co. Inc., West Point, Pa.
For more information, patients may call (866) NYP-NEWS.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and its academic partner, Weill Cornell Medical College. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, research, education and community service. NewYork-Presbyterian, which is ranked sixth on the U.S.News & World Report's list of top hospitals, also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center.
Contact
- Andrew Klein
- ank2017@med.cornell.edu
